UPDATE : Monday, September 7, 2020
상단여백
HOME Pharma
Eisai’s Aricept dominates dementia treatment market
  • By So Jae-hyeon
  • Published 2018.06.29 15:24
  • Updated 2018.06.29 15:24
  • comments 0

Eisai’s Aricept has comfortably secured the No. 1 place in the local dementia treatment market.

Donepezil is the leading ingredient in dementia treatments. The domestic drug companies quickly released Donepezil-containing generic drugs, but the original drug Aricept kept its lead in the first quarter.

According to IQVIA data, Aricept sold 16.79 billion won ($15.06 million) in the first quarter, up 10.6 percent from 15.18 billion won a year earlier.

Eisai has solidified Aricept’s market dominance by additionally releasing orally disintegrating tablet Aricept Evess. Aricept Evess sold 2.15 billion won in the first quarter, up 1.1 percent from 2.08 billion won a year earlier.

Domestic pharmaceutical firms have limited sales of donepezil-containing drugs.

Samjin Pharm’s Newtoin marked 1.5 billion won sales in the first quarter. It was up 8 percent from 1.4 billion won a year earlier but failed even to reach the sales of Aricept Evess.

Myung In Pharmaceutical’s Silvercept sold 1.28 billion won, up 8.1 percent from 1.18 billion won a year earlier. Whanin Pharm’s Whanin Donepezil posted a 20.5 percent year-on-year sales growth to 1.12 billion won in the first quarter.

Daewoong Pharmaceutical and Chong Kun Dang achieved meaningful growth in donepezil drugs. Daewoong released Beacept via Daewoong Bio. Beacept sales rapidly increased to 1.06 billion won in the first quarter, jumping from around 300 million won a year earlier. Daewoong manufactures Aricept for Eisai.

Chong Kun Dang’s Neuropezil saw a 10.8 percent sales decline, falling to 722 million won in the first quarter from 890 million won a year earlier.

Chong Kun Dang is a joint seller of Aricept, focusing on the drug sales to local clinics.

As the seller of the original drug is likely to see an accompanying growth of generic drugs, Chong Kun Dang’s Neuropezil might grow along with Aricept, observers said.

sjh@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>

Other articles by So Jae-hyeon
iconMost viewed
Comments 0
More
Please leave the first comment.
여백
여백
여백
Back to Top